NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe? COVID-19 Patients
- Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm
- Trial anticipated to initiate in Los Angeles area hospitals in Q2
- Proprietary automated ?GMP-in-a-Box?, an in-house manufacturing apparatus, enables rapidly scalable, off-the-shelf allogeneic mesenchymal stem cell product BM-Allo.MSC